Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer

Clinical Cancer Research

Volumn 11, Issue 3, 2005, Pages 1073-1085

  Malik, Gunjan ^a   Ward, Michael D ^a   Gupta, Saurabh K ^a   Trosset, Michael W ^b   Grizzle, William E ^c   Adam, Bao Ling ^a,d   Diaz, Jose I ^a   Semmes, O John ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b The College of William and Mary   (United States)

^c University of Alabama at Birmingham   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A2; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CONTROLLED STUDY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPOPROTEIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

APOLIPOPROTEIN A-II; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 12944252957     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004;119:174-86.
2. Carter HB. Prostate cancers in men with low PSA levels: must we find them? N Engl J Med 2004;350:2292-4.
3. Gambert SR. Prostate cancer. When to offer screening in the primary care setting. Geriatrics 2001;56:22-6, 29-31.
4. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
5. Platz EA, De Marzo AM, Giovannucci E. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem 2004;91:553-71.
6. Wiesner A. Detection of tumor markers with ProteinChip technology. Curr Pharm Biotechnol 2004;5:45-67.
7. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004;23:34-44.
8. Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF III, Liotta L. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol 2003;532:59-68.
9. Wright GL Jr. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002;2:549-63.
10. Grizzle WE, Semmes OJ, Bigbee WL, et al. Use of high throughput mass spectrographic methods to identify disease processes with emphasis on SELDI-TOF-MS methods. In: Patrinos G, Ansorg W, editors. Molecular diagnostics. Elsevier Press, Amsterdam; 2004.
11. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-502.
12. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
13. Qu Y, Adam BL, Yasui Y, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-43.
14. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
15. Banez LL, Prasanna P, Sun L, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003;170:442-6.
16. Wadsworth JT, Somers KD, Stack BC Jr, et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004;130:98-104.
17. Wadsworth JT, Somers KD, Cazares LH, et al. Serum protein profiles to identify head and neck cancer. Clin Cancer Res 2004;10:1625-32.
18. Petricoin EF III, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
19. Vlahou A, Laronga C, Wilson L, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003;4:203-9.
20. Ball G, Mian S, Holding F, et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 2002;18:395-404.
21. Cazares LH, Adam BL, Ward MD, et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002;8:2541-52.
22. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-8.
23. Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange Protein-Chips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 2003;100:12343-8.
24. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
25. Paweletz CP, Trock B, Pennanen M, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001;17:301-7.
26. Poon TC, Yip TT, Chan AT, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003;49:752-60.
27. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologie diseases and healthy persons. Proteomics 2003;3:2310-6.
28. Xiao X, Liu D, Tang Y, et al. Development of proteomic patterns for detecting lung cancer. Dis Markers 2003;19:33-9.
29. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and premalignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003;40:267-79.
30. Grizzle WE, Myers RB, Manne U, Stockard CR, Harkins LE, Srivastava S. Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia. In: Hanausek M, Walasze Z, editors. John Walker's methods in molecular medicine: tumor marker protocols. Totowa (NJ): Humana Press, Inc.; 1998. p. 161-79.
31. Grizzle WE, Myers RB, Manne U, Srivastava S. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. In: Hanausek M, Walasze, Z., editors. John Walker's methods in molecular medicine: tumor marker protocols. Totowa (NJ): Humana Press, Inc.; 1998. p. 143-60.
32. Gordon JI, Budelier KA, Sims HF, Edelstein C, Scanu AM, Strauss AW. Biosynthesis of human preproapolipoprotein A-II. J Biol Chem 1983;258:14054-9.
33. Scanu AM, Edelstein C, Wolf RH. Chimpanzee (Pan troglodytes) serum high density lipoproteins. Isolation and properties of their two major apolipoproteins. Biochim Biophys Acta 1974;351:341-7.
34. Bisgaier CL, Glickman RM. Intestinal synthesis, secretion, and transport of lipoproteins. Annu Rev Physiol 1983;45:625-36.
35. Tsao YK, Wei CF, Robberson DL, Gotto AM Jr, Chan L. Isolation and characterization of the human apolipoprotein A-II gene. Electron microscopic analysis of RNA:DNA hybrids, nucleotide sequence, identification of a polymorphic MspI site, and general structural organization of apolipoprotein genes. J Biol Chem 1985;260:15222-31.
36. Brewer HB Jr, Lux SE, Ronan R, John KM. Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex. Proc Natl Acad Sci U S A 1972;69:1304-8.
37. Deterding LJ, Cutalo JM, Khaledi M, Tomer KB. Separation and characterization of human high-density apolipoproteins using a non-aqueous modifier in capillary electrophoresis-mass spectrometry. Electrophoresis 2002;23:2296-305.
38. Lackner KJ, Edge SB, Gregg RE, Hoeg JM, Brewer HB Jr. Isoforms of apolipoprotein A-II in human plasma and thoracic duct lymph. Identification of proapolipoprotein A-II and sialic acid-containing isoforms. J Biol Chem 1985;260:703-6.
39. Niederkofler EE, Tubbs KA, Kiernan UA, Nedelkov D, Nelson RW. Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res 2003;44:630-9.
40. Schmitz G, Ilsemann K, Melnik B, Assmann G. Isoproteins of human apolipoprotein A-II: isolation and characterization. J Lipid Res 1983;24:1021-9.
41. Warden CH, Daluiski A, Bu X, et al. Evidence for linkage of the apolipoprotein A-II locus to plasma apolipoprotein A-II and free fatty acid levels in mice and humans. Proc Natl Acad Sci U S A 1993;90:10886-90.
42. Edelstein C, Halari M, Scanu AM. On the mechanism of the displacement of apolipoprotein A-I by apolipoprotein A-II from the high density lipoprotein surface. Effect of concentration and molecular forms of apolipoprotein A-II. J Biol Chem 1982;257:7189-95.
43. Jahn CE, Osborne JC Jr, Schaefer EJ, Brewer HB Jr. In vitro activation of the enzymic activity of hepatic lipase by apoA-II. FEBS Lett 1981;131:366-8.
44. Scanu AM, Lagocki P, Chung J. Effect of apolipoprotein A-II on the structure of high-density lipoproteins: relationship to the activity of lecithin:cholesterol acyl transferase in vitro. Ann N Y Acad Sci 1980;348:160-73.
45. Tailleux A, Duriez P, Fruchart JC, Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 2002;164:1-13.
46. Weng W, Breslow JL. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci U S A 1996;93:14788-94.
47. Aspinall JO, Bentel JM, Horsfall DJ, Haagensen DE, Marshall VR, Tilley WD. Differential expression of apolipoprotein-D and prostate specific antigen in benign and malignant prostate tissues. J Urol 1995;154:622-8.
48. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2004;91:54-69.
49. Lehrer S. Possible relationship of the apolipoprotein E (ApoE) epsilon4 allele to prostate cancer. Br J Cancer 1998;78:1398.
50. Myers RB, Oelschlager DK, Weiss HL, Frost AR, Grizzle WE. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J Urol 2001;165:1027-32.
51. Trougakos IP, Gonos ES. Clusterin/Apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002;34:1430-48.
52. Zhang SX, Bentel JM, Ricciardelli C, et al. Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers. J Urol 1998;159:548-54.
53. Blanco-Vaca F, Via DP, Yang CY, Massey JB, Pownall HJ. Characterization of disulfide-linked heterodimers containing apolipoprotein D in human plasma lipoproteins. J Lipid Res 1992;33:1785-96.
54. Vogel T, Guo NH, Guy R, et al. Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem 1994;54:299-308.
55. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 1998;153:911-9.
56. Diaz JI, Mora LB, Austin PF, et al. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology 1999;53:931-8.